By IDSE News Staff
Children from 12 to 15 years of age vaccinated with the Pfizer/BioNTech messenger RNA (mRNA) COVID-19 vaccine developed robust antibody responses, according to recent data reported from the companies.
The phase 3 trial enrolled 2,260 U.S. adolescents aged 12 to 15 years with or without prior evidence of SARS-CoV-2 infection. In the trial, 18 cases of COVID-19 were observed in the placebo group (n=1,129) versus none in the vaccinated group (n=1,131).
Vaccination with the